Literature DB >> 29621088

Treatment of Facial Infantile Hemangioma: Comparative Study Between Propranolol and Ethanolamine Oleate.

Thais Miguel do Monte Lameiro1, Rafael Denadai, João Carlos Pereira-Filho, Cesar Augusto Raposo-Amaral, Cassio Eduardo Raposo-Amaral.   

Abstract

BACKGROUND: Infantile hemangiomas (IH) are the most common benign vascular tumors in childhood. Approximately 10% to 15% of these tumors require drug or surgical intervention. There are many options for IH treatment, of which propranolol is currently considered the gold standard. This study aims to compare the therapeutic results of 2 distinct drugs (ethanolamine oleate and propranolol), in order to increase the available therapeutic arsenal for the treatment of IH, thereby benefiting a larger group of patients.
METHODS: A retrospective observational study was conducted to assess 16 patients with facial IH, allocated into 2 groups (n = 8). All patients met the same inclusion and exclusion criteria. The resulting evolution assessment was based on photographic documentation produced in a professional setting, and was performed before, during, and after treatment. Two measurement scales, photographic-based assessment of infantile hemangioma characteristics, and outcomes were used for comparison between the 2 therapeutic methods.
RESULTS: Both assessment methods did not present any significant statistical difference (P > 0.05) at 1 year of follow-up.
CONCLUSION: Both therapeutic modalities are able to offer the patient similar and satisfactory final esthetic results.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29621088     DOI: 10.1097/SCS.0000000000004573

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  1 in total

Review 1.  Effects of sclerosing agents on head and neck hemangiomas: A systematic review.

Authors:  Rúbia-Teodoro Stuepp; Fernanda-Marcello Scotti; Gilberto Melo; Etiene-de Andrade Munhoz; Filipe Modolo
Journal:  J Clin Exp Dent       Date:  2019-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.